BIBiocon532523Pharmaceuticals, biosimilars

Biocon's executive chairperson Kiran Mazumdar Shaw said H2 FY will see much stronger growth than H1, driven by biosimilars, insulin and new launches

By ScoutQuest · Thu 5 Nov 2026, 11:45 AM IST · 1 min read

Brazil PDP contract value

$400 million

Revenue deferred to next quarter

5% of revenue

Biosimilars share of biopharma business

80%

Generics share of biopharma business

less than 20%

Target EBITDA margin

mid-20s EBITDA margin

Heard on business television between 11:45:20 - 11:48:20 IST.

• Said H1 showed slow steady progress similar to Q1, with a strong uptick expected in H2
• Noted about 5% revenue recognition was deferred to next quarter due to logistics reasons
• Said second insulin fill-finish line in Malaysia has commenced supplies, aiding insulin growth (glargine and aspart) in H2
• Said Europe launch of Portumap expected in Q4 FY, plus a $400 million PDP contract won in Brazil to start generating revenue from Q4
• Guided to mid-20s EBITDA margin with EBITDA growth commensurate with strong double-digit revenue growth in H2
• Said generics business (less than 20% of biopharma business) grew well, aided by Liraglutide, while biosimilars contribute 80%

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev